Magdalena Sroka1, Harini Bagavant1, Indranil Biswas1, Abigail Ballard1, Umesh S Deshmukh2. 1. Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA. 2. Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA. umesh-deshmukh@omrf.org.
Abstract
OBJECTIVES: The structural domains of Ro52, termed the RING, B-box, coiled coil (CC) and B30.2/SPRY are targets of anti-Ro52 in multiple autoimmune disorders. In Sjögren's syndrome patients, the presence of anti-Ro52 is associated with higher disease severity, and in mice, they induce salivary gland hypofunction. This study was undertaken to investigate whether immune responses against different domains of Ro52, influences salivary gland disease in mice. METHODS: Female NZM2758 mice were immunised with Ro52 domains expressed as recombinant fusion proteins with maltose binding protein (MBP) [MBP-RING-B-box, MBP-CC, MBP-CC(ΔC19), MBP-B30.2/SPRY]. Sera from immunised mice were studied for IgG antibodies to Ro52 by immunoprecipitation, and to salivary gland cells by immunofluorescence. Pilocarpine-induced saliva production was measured to evaluate salivary gland function. Submandibular glands were investigated by histopathology for inflammation and by immune-histochemistry for IgG deposition. RESULTS: Mice immunised with different Ro52-domains had comparable reactivity to Ro52 and to salivary gland cells. However, only mice immunised with the CC domain and its C-terminal truncated version CC(ΔC19) showed a significant drop in saliva production. None of the mice developed severe salivary gland inflammation. The salivary gland hypofunction significantly correlated with increased intra-lobar IgG deposits in the submandibular salivary glands. CONCLUSIONS: Our data demonstrate that epitope specificity of anti-Ro52 antibodies plays a critical role in the induction of glandular dysfunction. Clearly, screening Sjögren's syndrome patients for relative levels of Ro52 domain specific antibodies will be more informative for associating anti-Ro52 with clinical measures of the disorder.
OBJECTIVES: The structural domains of Ro52, termed the RING, B-box, coiled coil (CC) and B30.2/SPRY are targets of anti-Ro52 in multiple autoimmune disorders. In Sjögren's syndrome patients, the presence of anti-Ro52 is associated with higher disease severity, and in mice, they induce salivary gland hypofunction. This study was undertaken to investigate whether immune responses against different domains of Ro52, influences salivary gland disease in mice. METHODS: Female NZM2758 mice were immunised with Ro52 domains expressed as recombinant fusion proteins with maltose binding protein (MBP) [MBP-RING-B-box, MBP-CC, MBP-CC(ΔC19), MBP-B30.2/SPRY]. Sera from immunised mice were studied for IgG antibodies to Ro52 by immunoprecipitation, and to salivary gland cells by immunofluorescence. Pilocarpine-induced saliva production was measured to evaluate salivary gland function. Submandibular glands were investigated by histopathology for inflammation and by immune-histochemistry for IgG deposition. RESULTS:Mice immunised with different Ro52-domains had comparable reactivity to Ro52 and to salivary gland cells. However, only mice immunised with the CC domain and its C-terminal truncated version CC(ΔC19) showed a significant drop in saliva production. None of the mice developed severe salivary gland inflammation. The salivary gland hypofunction significantly correlated with increased intra-lobar IgG deposits in the submandibular salivary glands. CONCLUSIONS: Our data demonstrate that epitope specificity of anti-Ro52 antibodies plays a critical role in the induction of glandular dysfunction. Clearly, screening Sjögren's syndrome patients for relative levels of Ro52 domain specific antibodies will be more informative for associating anti-Ro52 with clinical measures of the disorder.
Authors: P Ghillani; C André; C Toly; A M Rouquette; D Bengoufa; P Nicaise; C Goulvestre; A Gleizes; M A Dragon-Durey; M A Alyanakian; P Chretien; S Chollet-Martin; L Musset; B Weill; C Johanet Journal: Autoimmun Rev Date: 2011-04-05 Impact factor: 9.754
Authors: R N MacSween; R B Goudie; J R Anderson; E Armstrong; M A Murray; D K Mason; M K Jasani; J A Boyle; W W Buchanan; J Williamson Journal: Ann Rheum Dis Date: 1967-09 Impact factor: 19.103
Authors: Debashish Danda; Rohan Sharma; Dat Truong; Kristi A Koelsch; Biji T Kurien; Harini Bagavant; Umesh Deshmukh; C Erick Kaufman; David M Lewis; Donald U Stone; Lida Radfar; Astrid Rasmussen; Kathy L Sivils; Robert H Scofield Journal: Clin Exp Rheumatol Date: 2017-02-20 Impact factor: 4.473
Authors: T P Gordon; G Kinoshita; D Cavill; C Keech; A Farris; K Kaufman; J McCluskey; A Purcell Journal: Scand J Immunol Date: 2002-08 Impact factor: 3.487
Authors: L Strandberg; O Winqvist; S-E Sonesson; S Mohseni; S Salomonsson; K Bremme; J P Buyon; H Julkunen; M Wahren-Herlenius Journal: Clin Exp Immunol Date: 2008-08-22 Impact factor: 4.330
Authors: Claudia M Trujillo-Vargas; Laura Schaefer; Jehan Alam; Stephen C Pflugfelder; Robert A Britton; Cintia S de Paiva Journal: Ocul Surf Date: 2019-10-20 Impact factor: 5.033
Authors: Harini Bagavant; Marta Trzeciak; Indranil Biswas; Joanna A Papinska; Katarzyna Cizio; Umesh S Deshmukh Journal: J Oral Pathol Med Date: 2022-07-12 Impact factor: 3.539
Authors: Athanasios Gkoutzourelas; Christos Liaskos; Maria G Mytilinaiou; Theodora Simopoulou; Christina Katsiari; Alexandra Tsirogianni; Dimitrios Daoussis; Thomas Scheper; Wolfgang Meyer; Dimitrios P Bogdanos; Lazaros I Sakkas Journal: Front Immunol Date: 2018-12-07 Impact factor: 7.561